|
Over 40% Haryana pharma units implement revised Schedule M; Rest to comply in 8-10 months: HPMA
|
|
Peethaambaran Kunnathoor, Chennai
October 07 , 2026
|
|
|
In a major operational breakthrough for northern India’s drug manufacturing sector, over 40 per cent of the total 150 pharmaceutical manufacturing units in Haryana have successfully implemented the revised Schedule M standards.
The remaining 60 per cent of the state’s manufacturing plants are currently undergoing comprehensive facility upgrades and are projected to achieve complete regulatory compliance within the next eight to ten months, according to RL Sharma, president of the Haryana Pharmaceutical Manufacturers Association (HPMA).
In a telephonic interaction with Pharmabiz, Sharma stated that financial constraints remain the single biggest hurdle in implementing the revised Schedule M. He emphasized that were it not for capital bottlenecks, the entire pharmaceutical industrial sector across the state would have already completed the transformation to the revised Good Manufacturing Practices (GMP) norms already.
Highlighting the sector’s financial vulnerability, Sharma said that central government funding remains the critical lifeline required to accelerate remaining plant upgrades. He reiterated that small and micro enterprises are eagerly waiting for targeted central financial assistance to overcome liquidity challenges and execute capital-intensive plant restructuring without causing severe operational strain.
Acknowledging the institutional support driving the sector forward, the HPMA chief expressed immense appreciation for the state government and the regulatory authorities. "We are getting immense support from the state government and from the regulatory department. The drug controller Ripan Mehta is giving all technical guidance for the industry. The former DCs, NA Ahooja and Lalit Kumar Goel, are also giving guidance for improving the industry. Actually, the government wants to upgrade the industry by implementing the revised Schedule M process," Sharma told Pharmabiz.
Despite widespread financial strain, the industry has demonstrated remarkable resilience against insolvency. When asked about potential plant closures driven by non-viability during the upgrade drive, Sharma revealed that only five manufacturing units across the state have downed their shutters so far, proving that the vast majority of local entrepreneurs remain committed to survival and compliance.
Touching upon the regulatory landscape, Sharma expressed strong confidence in the Haryana Pharmaceutical and Medical Devices Manufacturing Policy. He said that the policy framework was specifically engineered to cushion local manufacturers, instilling deep confidence among entrepreneurs that the state administration will extend every possible operational and infrastructural support to safeguard the sector.
On the future trajectory of the region's pharmaceutical landscape, Sharma highlighted the upcoming Karnal Pharma Park project, for which he serves as the chairman of the Special Purpose Vehicle (SPV). He disclosed that land acquisition for the prestigious cluster will be finalized within the next two months, adding that both state authorities and the central government are extending active administrative and financial backing to establish Haryana as a leading pharmaceutical manufacturing hub in the country.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|